Institutional filer profile
Broadwood Capital Inc Insider Trades
Broadwood Capital Inc has reported 4 open-market purchases on SEC Form 4 and is a net buyer of $9,455,818 across 2 companies. The most recent open-market transaction was reported on Nov 17, 2026. Source: SEC Form 4 filings.
Latest reported as Corporate insider of Lineage Cell Therapeutics, Inc. (LCTX).
SEC-reported filing activity is provided for research purposes and is not investment advice.
- Purchase filings
- 4
- Reported companies
- 2
- Net open-market value
- $9,455,818
- Latest transaction
- Nov 17, 2026
Affiliated corporations
Reported company relationships
Transaction history
Open-market Transactions
Common questions
Broadwood Capital Inc insider trading FAQ
- Is Broadwood Capital Inc buying or selling stock?
- Across all SEC Form 4 open-market filings on record, Broadwood Capital Inc is a net buyer of $9,455,818, with 4 open-market purchases reported. The latest transaction was reported on Nov 17, 2026.
- Which companies does Broadwood Capital Inc report insider trades for?
- Broadwood Capital Inc has reported open-market trades in Lineage Cell Therapeutics, Inc. (LCTX), Insight Molecular Diagnostics Inc. (IMDX). The latest SEC-reported relationship is Corporate insider of Lineage Cell Therapeutics, Inc. (LCTX).
- Where does Broadwood Capital Inc's insider trading data come from?
- Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under filer CIK 1278387, and refreshes this page daily.
